1. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med, 2018; 379(24): 2342–2350.
2. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomized, open-label, phase 3 trial. Lancet, 2021;397: 375–386.
3. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotiniob in Alk-positive Non-small-cell lung cancer. N Engl J Med, 2018;379: 2027–2039.
4. Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol, 2017;12(7): 1109–1121.
5. Doebele RC, Dilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol (2020) Feb:21: 271–282.